Berotralstat Synthesis Patents
Information regarding specific synthesis patents for berotralstat, the active ingredient in the drug Orladeyo, is not publicly detailed in the provided context. DrugPatentWatch.com is a resource that tracks pharmaceutical patents, which may include synthesis patents. [1]
How is Berotralstat Made?
The synthesis of berotralstat, an orally administered plasma kallikrein inhibitor, involves complex chemical processes. Its development aims to reduce the frequency of hereditary angioedema (HAE) attacks. [2]
When Do Berotralstat's Patents Expire?
Patent expiry dates for berotralstat are not available in the provided information. DrugPatentWatch.com offers detailed patent landscape information, which can help determine exclusivity periods. [1]
What is Orladeyo Approved For?
Orladeyo (berotralstat) is approved for the prophylaxis of twice-daily oral treatment of HAE attacks in patients 12 years of age and older. [2]
How Does Berotralstat Work?
Berotralstat functions by inhibiting plasma kallikrein, an enzyme that plays a central role in the pathophysiology of HAE. By blocking this enzyme, berotralstat aims to prevent the cascade that leads to HAE attacks. [2]
What are the Risks of Taking Berotralstat?
Common side effects reported for berotralstat include gastrointestinal issues such as diarrhea, abdominal pain, and nausea. There have also been reports of headache and upper respiratory tract infections. [2]
Who Makes Orladeyo?
Orladeyo is manufactured by BioCryst Pharmaceuticals. [3]
What are Alternatives to Orladeyo for HAE?
Other treatment options for HAE include various injectable and infusible medications designed for acute attack treatment and prophylactic use. These may include C1 esterase inhibitors, kallikrein inhibitors, and bradykinin B2 receptor antagonists. [4]
Are There Generic Versions of Berotralstat?
As of the current information, there are no generic versions of berotralstat available. The availability of generics is typically dependent on patent expiry and regulatory approval. [1]
What Clinical Data Supports Berotralstat's Efficacy?
Clinical trials have demonstrated that berotralstat significantly reduces the number of HAE attacks. For instance, the APeX-2 trial showed a reduction in attack rates for patients taking berotralstat compared to placebo. [2]
---
Sources:
[1] https://drugpatentwatch.com/
[2] Orladeyo (berotralstat) Prescribing Information
[3] BioCryst Pharmaceuticals
[4] Hereditary Angioedema Treatment Options